Table 2.

Univariate Analyses of Cardiovascular Mortality

Factor	No. of Patients	No. of Treatment Failures	Cumulative Incidence			Fine and Gray's Models
			9-Year Failure Rate (%)	95% CI	P*	Unadjusted HR	95% CI	P†
Treatment arm
Arm 2	468	65	11.4	8.4 to 14.3
Arm 1	477	52	8.4	5.8 to 11.0	.17	0.77	0.53 to 1.11	.16
Age, years
< 70	453	38	6.0	3.7 to 8.2
≥ 70	492	79	13.6	10.5 to 16.8	.0001	2.08	1.41 to 3.06	.0002
Prevalent CVD
No	687	54	6.5	4.5 to 8.4
Yes	253	62	18.8	13.9 to 23.6	< .0001	3.24	2.25 to 4.66	< .0001
Prevalent HTN
No	632	69	8.4	6.1 to 10.6
Yes	309	47	12.8	9.1 to 16.6	.09	1.36	0.94 to 1.97	.10
Prevalent DM
No	765	85	8.8	6.7 to 10.9
Yes	81	21	22.4	13.2 to 31.6	.0003	2.40	1.49 to 3.86	.0003
BMI, kg/m2
< 25	241	30	10.0	6.0 to 13.9
≥ 25 to < 30	402	53	11.0	7.8 to 14.1		1.05	0.67 to 1.65	.82
≥ 30	145	20	9.5	4.6 to 14.5	.94	1.10	0.63 to 1.93	.73
Race
Black	82	12	10.0	3.4 to 16.7
Other	863	105	9.8	7.8 to 11.9	.61	0.86	0.48 to 1.55	.62
Prostatectomy
No	806	109	10.8	8.6 to 13.0
Yes	139	8	4.5	1.0 to 8.1	.017	0.42	0.21 to 0.87	.019
Nodal involvement
No	682	92	10.7	8.3 to 13.1
Yes	263	25	7.7	4.5 to 11.0	.048	0.66	0.42 to 1.02	.06
Acid phosphatase
Not elevated	634	78	9.4	7.1 to 11.8
Elevated	311	39	10.8	7.2 to 14.3	.83	1.03	0.70 to 1.51	.89
Gleason score
2-6	254	37	10.5	6.7 to 14.3
7	332	41	8.2	5.2 to 11.3		0.87	0.56 to 1.36	.54
8-10	276	29	10.4	6.8 to 14.1	.52	0.74	0.45 to 1.20	.22
Clinical stage
A/B	268	19	5.7	2.9 to 8.6
C	677	98	11.6	9.1 to 14.1	.001	2.20	1.34 to 3.60	.002

Abbreviations: HR, hazard ratio; CVD, cardiovascular disease; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.

^*P value determined using Gray's test statistic.

^†P value determined using χ² test.